Discussing AxSpA: Episode 3

Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of COMBIO, or Combination of Targeted Therapies, in clinical settings. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.